Skip Navigation


Annals of Oncology Advance Access originally published online on May 26, 2009
Annals of Oncology 2009 20(7):1281; doi:10.1093/annonc/mdp278
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/7/1281    most recent
mdp278v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wong, M.
Right arrow Articles by Tan, E.-H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wong, M.
Right arrow Articles by Tan, E.-H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

letters to the editor

Travel warning with capecitabine

The first 10% of the full text of this article appears below.

Capecitabine has been shown to have single-agent activity in recurrent and metastatic nasopharyngeal carcinoma. Significantly better survival was observed in patients who had severe hand–foot syndrome treated with capecitabine [1]. Modifying the dosing schedule can be used to manage hand–foot syndrome . . . [Full Text of this Article]

M. Wong, S.-P. Choo* and E.-H. Tan

Department of Medical Oncology, National Cancer Centre Singapore, Singapore

* E-mail: choosupin@nccs.com.sg)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?